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A 32-year-old woman with multiple sclerosis (MS) presents to her GP with a five-day 
history of numbness and weakness in the right leg. She feels well in herself and 
does not describe any symptoms to suggest an intercurrent infection. She has been 
taking weekly intramuscular injections of interferon-β1a for the last 18 months and 
reports flu-like symptoms that can last for up to 24 hours after each dose. She asks if 
there is a need to change her treatment and what alternatives are available. 
 
Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disorder of the 
central nervous system affecting over 2 million people worldwide.[1] It is a major 
cause of physical disability in young adults and has profound implications for 
cognition, emotional well-being and employment. Patients commonly present with 
unilateral visual loss (due to optic neuritis), double vision, sensory symptoms, limb 
weakness or imbalance.[2] The diagnosis is based on clinical features and MRI 
findings, sometimes supported by lumbar puncture and other investigations.[2, 3] 
Nearly 80-85% of people with MS experience a relapsing course with episodes of 
new or worsening neurological symptoms lasting at least 24 hours followed by full or 
partial recovery, in the absence of fever or infection (attacks or relapses).[3] 
Untreated, most people with relapsing MS develop disability over time due to 
incomplete recovery from relapses, or a change in disease course to progressive 
MS, with a steady increase in disability. In 10-15% of people with MS, the disease is 
progressive from onset (primary progressive MS [PPMS]). [Box 1] 
 
What treatments are available for MS? 
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Currently, 15 disease-modifying therapies (DMTs) are licenced for relapsing MS, 
including five preparations of interferon-β and three preparations of glatiramer 
acetate [2, 4]. A number of oral and monoclonal antibody therapies for MS have 
become available in the last decade (Figure 1). Ocrelizumab [5], the first treatment 
for PPMS, has recently been licenced. 
The DMTs have varying mechanisms of action (Supplementary Box) with 
immunosuppressive and immunomodulatory effects that target: 
- lymphocyte number (alemtuzumab, ocrelizumab, cladribine); 
- lymphocyte proliferation (teriflunomide, mitoxantrone); 
- lymphocyte trafficking (fingolimod, natalizumab); 
- cytokine production (interferon-β, glatiramer acetate). 
According to the regulatory agencies licencing, DMTs may have different indications 
(Box 1).  
International guidelines on starting, switching and stopping DMTs in people with MS 
(Box 2) recommend offering DMTs to patients with active relapsing MS. [6–8] No 
treatment is advised for patients with inactive MS [8]. The ECTRIMS/EAN and AAN 
guidelines recommend offering interferon-β or glatiramer acetate in patients with a 
clinically isolated syndrome, i.e. the first episode of neurological symptoms 
suggestive of MS with brain MRI abnormalities (indicating a high-risk of MS), to delay 
the second attack, and ocrelizumab in patients with PPMS.[6, 7] 
 
How well do they work? 
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There is moderate to high quality evidence from phase III randomised controlled 
trials and systematic reviews [9, 10] that DMTs reduce the relative risk of developing 
relapses (Table 1), accumulation of new brain MRI lesions, and disability progression 
over 2-3 years in active relapsing MS, compared with placebo, or an active 
comparator (interferon-β).[4] The use of relative measures over absolute measures 
is preferred to compare the efficacy of two treatments in MS because the former 
appear to be more stable across populations of patients with different relapse and 
MRI measures of disease activity. [11, 12] When recommending starting a DMT, a 
clinician might discuss with the patient that being on that medication – rather than 
being on no medications at all - will reduce the risk of developing relapses by a 
certain percentage as found in large clinical trials (Table 1). DMTs generally do not 
improve established symptoms of MS, although a pivotal trial [13] showed that 
alemtuzumab treated patients were more than twice as likely as interferon-β treated 
patients to experience 6-month confirmed disability improvement (28.8% vs 12.9%, 
Hazard Ratio [HR]= 2.57, p=0.0002), and a post-hoc study from another pivotal trial 
showed that natalizumab [14] improved disability by 69% (HR = 1.69; 95% 
Confidence Intervals [CI] 1.16–2.45; p = 0.006) versus placebo in a subset of 
patients with baseline expanded disability status scale scores ≥ 2.0.  
Clinical trials in MS are typically of 2-3 years duration and the long-term benefits of 
DMTs are uncertain. Observational studies report conflicting evidence on the impact 
of interferon-β in reducing long-term disability and development of secondary 
progressive MS [15, 16].  
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Few studies have directly compared different DMTs. A systematic review of head-to-
head trials (including 5 randomised controlled trial and 2858 participants) comparing 
interferon-β preparations and glatiramer acetate found a similar effect on relapses 
and disability progression, although secondary MRI endpoints favoured interferon-β. 
[17] In separate phase III randomised controlled trials, interferon-β had similar 
efficacy to teriflunomide, and was less effective than fingolimod, alemtuzumab and 
ocrelizumab. A Cochrane network meta-analysis in 2015 (including 39 randomised 
controlled trials and 25,113 participants) looked at the efficacy of 15 DMTs (including 
three different preparations of interferon-β). It found that, over a 24-month period, 
alemtuzumab (risk ratio [RR] versus placebo 0.46, 95% CI 0.38-0.55), natalizumab 
(RR 0.56, 95% CI 0.47-0.66), and fingolimod (RR 0.72, 95% CI 0.64-0.81) were 
more effective for preventing relapses based on moderate to high-quality evidence, 
and natalizumab (RR 0.64, 95% CI 0.49-0.85) was more effective for preventing 
disability worsening based on moderate quality evidence. [9] The main limitations of 
this review were that the majority of the incuded studies were sponsored by 
pharmaceutical companies and had a short duration in time (median 24 months). 
Since the publication of this Cochrane review, new clinical trials in relapsing MS 
have been reported.[5, 18, 19] In 2017, a network meta-analysis (including 33 
studies and 21,768 participants with relapsing MS) was carried out by the US 
Institute for Clinical and Economic Review on 16 DMTs including 5 formulations of 
interferon-β and 3 of glatiramer acetate and the newly approved ocrelizumab (not 
reported in the Cochrane review). The analysis showed that, between the FDA 
licenced drugs for relapsing MS, alemtuzumab, natalizumab, and ocrelizumab had 
the greatest reduction in the annualised relapse rates (approximately 70% reduction 
compared to placebo), fingolimod, and dimethyl fumarate were the next most 
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effective (47% to 54% reduction) and the interferons, glatiramer acetate and 
teriflunomide were less effective (17% to 37% reduction). This analysis is limited by 
the short-term follow-ups of the included studies and the lack of head-to-head trials. 
Furthermore, it pointed out that the evolving MS diagnostic criteria over the past 2 
decades have caused important variation among the studied patient populations 
across trials.  
 
What are the harms? 
Very common (≥10% of patients) or common (≥1% to <10% of patients) adverse 
reactions of DMTs, as reported in the relevant summaries of product characteristics, 
include: flu-like symptoms (interferon-β); headache (interferon-β, fingolimod); 
gastrointestinal upset (dimethyl fumarate, teriflunomide); injection site reactions 
(interferon-β, glatiramer acetate). These are generally mild but can impact on 
adherence, and sometimes require a change of treatment. Infusion reactions occur 
commonly with alemtuzumab and ocrelizumab.  
Interferon-β and glatiramer acetate have an excellent long-term safety profile, as 
shown by long-term observational studies.[20–22] The oral and monoclonal antibody 
treatments for MS can have serious adverse reactions including opportunistic 
infections, cardiac arrhythmias, hepatotoxicity and secondary autoimmunity (Table 
1), and the long-term safety profile of these DMTs is unknown. Daclizumab, an anti-
CD25 monoclonal antibody, has recently been withdrawn following cases of severe 
liver injury and immune-mediated encephalitis not observed in phase III clinical trials. 
Post-authorisation safety studies and pharmacovigilance are essential for all newly 
approved DMTs, and can lead to marketing authorisation changes by the regulatory 
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agencies. DMTs may be associated with serious adverse reactions (see below). 
Natalizumab and alemtuzumab are subject to a Risk Evaluation and Mitigation 
Strategy (REMS) by the FDA, requiring training and support for healthcare providers 
to monitor patients during treatment to reduce the occurrence and/or severity of 
serious risks.  
 
Progressive multifocal leukoencephalopathy 
Progressive multifocal leukoencephalopathy (PML), due to reactivation of the John 
Cunningham virus (JCV), is an opportunistic brain infection that can complicate 
treatment with natalizumab and is associated with high rates of death or disability. 
JCV serostatus and antibody index should be checked before starting natalizumab 
(and periodically during treatment) to stratify PML risk. PML has rarely been reported 
in patients with fingolimod (estimated risk <1:10,000) and dimethyl fumarate who 
have not been treated with natalizumab.  
 
Cardiac arrhythmias 
Fingolimod causes first-dose bradycardia (~1-2%), and rarely transient heart block 
(<0.5%). An electrocardiogram should be obtained prior to starting treatment and the 
first dose administered with heart rate monitoring for 6 hours after the first dose. 
Cases of ventricular tachycardia and sudden cardiac death have also been reported 
with fingolimod. Fingolimod should be avoided in patients with a history of ischemic 
heart disease or cardiac arrhythmias. 
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Hepatotoxicity 
Deranged liver function tests (LFTs) commonly occur with a number of DMTs 
(particularly interferon-β, dimethyl fumarate, fingolimod). Individual cases of fatal liver 
injury have been reported with leflunomide (the pro-drug of teriflunomide).  
Teriflunomide should be avoided in people with a history of liver disease. 
 
Secondary autoimmunity 
Autoimmune thyroid disease, immune thrombocytopenic purpura and 
glomerulonephritis may occur in people treated with alemtuzumab, most often in the 
second or third year after starting treatment (risk of secondary autoimmunity ~50% at 
5 years).  
 
Malignancy 
DMTs should not be prescribed in patients with an active malignancy, and the safety 
in patients with a history of cancer is uncertain. Fingolimod is associated with an 
increased risk of skin cancers, particularly basal cell carcinoma. Mitoxantrone is 
associated with an increased risk of acute myeloid leukaemia (0.5-1%), and possibly 
solid-organ cancers. The long-term risk of cancer with other DMTs is unknown. 
 
How are they given and monitored? 
DMTs are prescribed and monitored in secondary care, often through specialist MS 
clinics with neurologists, nurse specialists and pharmacists. The route 
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(subcutaneous or intramuscular injection, oral, intravenous) and frequency of 
administration differs by the drug. A discussion of the risks and benefits of treatment 
is important. Figure 2 lists important considerations when selecting DMTs. Blood 
monitoring is required for all DMTs (except glatiramer acetate), particularly full blood 
count (to detect lymphopenia) and liver function tests. The frequency and type of 
blood test and other monitoring, such as brain MRI or urine test, are mandated by 
regulatory authorities (Table 1 and Tips for safer prescribing Box).  
Most DMTs require ongoing treatment, with return of disease activity if the drug is 
interrupted or stopped. Some DMTs have immune-reconstitution properties with 
sustained effects on relapse rates and MRI activity in the absence of ongoing 
treatment (alemtuzumab, cladribine).  Adherence to treatment is important and 
DMTs may be changed in patients with side-effects. There is no guidance on 
stopping treatment; this is usually decided by the treating neurologist in discussion 
with the patient based on the response and side effects (Figure 2). 
Periodic clinical reviews to check for relapses and/or disability progression plus MRI 
scanning are used to monitor response to treatment. Evidence of disease activity on 
MRI is associated with an increased risk of disability progression, even in patients 
who are stable clinically [23, 24]. Some neurologists use the target of “no evidence of 
disease activity” (NEDA) when treating relapsing MS, recommending a change of 
treatment if there are ongoing relapses, new MRI activity or disability progression 
[25]. There is conflicting evidence on the benefits of this approach [26, 27]. 
 
How cost-effective are they? 
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DMTs account for over half of direct medical costs in people with MS.[28] There is 
wide variation in the cost of DMTs between countries. The cost of DMTs has 
increased dramatically in the United States over the last 10 years with 10-15% 
increase annually. The annual cost of most DMTs now exceeds US$70,000/year. 
[28] A number of studies have found that DMTs are not cost-effective at accepted 
economic thresholds. [28] A recent analysis from the Institute of Clinical and 
Economic Review found that among the currently available DMTs, alemtuzumab 
may be most cost-effective because of the combination high-efficacy and unique 
dosing strategy (two cycles of treatment over 2 years with further treatment given 
only if needed).[10] Lower drug pricing (as in the United Kingdom [29]), the 
availability of generics [30], off-label prescribing (e.g. rituximab [31]), and the 
increasing use of DMTs that do not require ongoing maintenance treatment may 
improve cost-effectiveness. 
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What you need to know 
 People with active relapsing MS should be considered for DMTs early in the 
course to prevent relapses, new brain and spinal cord lesions and worsening 
neurological disability. 
 Some DMTs are associated with potentially serious adverse reactions and 
careful monitoring is required, usually through a specialist MS clinic. 
 Newer DMTs have higher efficacy than older DMTs, but there are insufficient 
data about their effectiveness and risks in the long-term.  
 The first treatment for primary progressive MS has recently been approved. 
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Tips for safer prescribing 
 DMTs are contraindicated in patients with active infections or 
malignancy, and in patients taking other immunosuppressants.[32] 
 Fingolimod has interactions with CYP3A4 enzyme inhibitors (azole 
antifungals, macrolides antibiotics, protease inhibitors) and inducers 
(rifampicin, carbamazepine, St John’s wort), and pharmacodynamic 
interactions with beta blockers and calcium channel blockers. 
 Follow regulatory authority guidance on blood, urine and MRI monitoring 
requirements. 
 MRI monitoring is mandatory in patients treated with DMTs associated 
with a risk of PML (natalizumab, fingolimod, dimethyl fumarate), on at 
least an annual basis, and every 3-6 months in natalizumab-treated 
patients at high-risk of PML.[33] 
Pregnancy and breastfeeding 
Women taking DMTs should be counselled to use effective contraception. 
DMTs are usually discontinued prior to conception, although interferon-β and 
glatiramer acetate may be safe during conception and pregnancy. [34] The 
EMA recently updated the label of branded glatiramer acetate (Copaxone®) to 
remove pregnancy as a contraindication. Teriflunomide is teratogenic and an 
accelerated elimination procedure may be required prior to conception because 
of its long half-life. Preconception planning to make decisions regarding DMTs 
and obstetric care should be considered in women with MS.[35] 
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Vaccinations 
Live or live-attenuated vaccines should be avoided in patients taking most 
DMTs. Patients who are Varicella-Zoster virus IgG negative should be 
immunised, particularly before treatment with fingolimod or cladribine.[32]  
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Tips for patients 
 Several disease-modifying therapies with moderate (30-50% reduced 
relapse rate) or high (>50% reduced relapse rate) efficacy are available for 
relapsing MS. Discuss the options with a specialist MS team to select the 
treatment that fits best with your preferences. 
 DMTs do have potential side effects, some of which are serious.  
 Almost all of the DMTs have monitoring requirements such as routine blood 
tests, but some treatments need more monitoring than others such as 
special blood tests, urine tests and brain MRIs. Your MS Team will explain 
to you what kind of monitoring you require. 
 New symptoms might mean a change of DMT is required. Know how to 
contact your MS nurse specialist or neurologist if you have new or 
worsening symptoms between clinic visits.  
 MRI scans are an important part of deciding how well DMTs are working. 
When was your last MRI? 
 Some DMTs are unsafe for women who are pregnant or breastfeeding. If 
you are considering becoming pregnant, then discuss this with your MS 
team.  
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Education into practice 
 Are all your patients with active relapsing MS referred to a neurologist for a 
discussion regarding DMTs? 
 Are women you see who take DMTs using effective contraception? 
 Consider placing an alert on the electronic patient record for people 
receiving DMTs so that complications of treatment are recognised promptly 
in patients presenting acutely in primary or secondary care. 
 
How patients were involved in the creation of this article 
We asked two patients who attend our specialist MS clinic to comment on the 
draft manuscript and develop the Tips for Patients section. They highlighted the 
importance of early referral to a specialist MS team, the importance of lifestyle 
factors and burden of monitoring when selecting DMTs, and 
contraception/preconception counselling in women with MS.  
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FIGURE AND BOX LEGEND 
 
Figure 1. Timeline of the approved disease-modifying therapies  
The figure shows the timeline of the approved DMTs for relapsing MS according by the FDA (on the 
top) and the EMA (on the bottom). 
  
DMT= disease-modifying therapy; EMA= European Medicines Agency; FDA= Food and Drug 
Administration; MS= multiple sclerosis. 
 
± Daclizumab (Zynbrita®, Biogen) has been withdrawn from the market by Biogen in March 2018, due 
to cases of encephalitis and meningoencephalitis. 
 
§ Glatiramer acetate was approved after Mutual Recognition Procedure in Europe (the UK was the 
reference member state) and not formally by the EMA. Glatiramer acetate (Copaxone®, Teva) was 
approved in the UK in 2000.  
 
# Mitoxantrone has been authorised in the EU via national procedures and not initially formally 
reviewed by the EMA. In 2016, the EMA was asked to harmonise the marketing authorisations in the 
EU. The EMA declared that Mitoxantrone is indicated for treatment of patients with highly active 
relapsing MS associated with rapidly evolving disability where no alternative therapeutic options exist. 
 
 
(Syringe symbol) = Injectable drug 
 (Capsule symbol) = Oral drug 
 (Intravnous-drip symbol) = Intravenous 
drug 
 
 
Figure 2. Factors influencing disease-modifying therapy choices in multiple 
sclerosis 
 
 
Box 1.  An approach to treating multiple sclerosis 
The box shows an approach to treat relapsing MS according to the EMA, with a mention to the FDA 
indications. The EMA allows the prescription of some treatments (natalizumab, fingolimod, cladribine, 
mitoxantrone) to patients with highly-active MS. Of note, the FDA does not group patients according 
to disease activity (i.e. active or highly active) but rather on patients’ response to DMTs (i.e. if patients 
develop relapses or new/enlarged or gadolinium enhancing lesions while on DMTs). 
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DMTs can only be prescribed by MS experts (secondary care). Standard care should be carried out 
by both primary and secondary care. References: Brownlee WJ 2017 [2] and Galea I 2015 [27]. 
 
Abbreviations: DMT= disease-modifying therapy; CIS= Clinically Isolated Syndrome; CNS= central 
nervous system; DMT= disease-modifying therapy; EMA= European Medicines Agency; FDA= food 
and Drug Administration; MRI= magnetic resonance imaging; MS= multiple sclerosis; PPMS= primary 
progressive multiple sclerosis; SPMS= secondary progressive multiple sclerosis; Std= Standard.  
  
* The FDA allows the use of alemtuzumab only if patients have not had an adequate response to two 
or more of the other approved DMTs. 
**Fingolimod is only approved first-line in Europe for highly active MS 
*** Cladribine is not approved by the FDA. 
^ Mitoxantrone is approved by the EMA for treatment of patients with highly active relapsing MS 
associated with rapidly evolving disability where no alternative therapeutic options exist. The FDA 
allows the use of mitoxantrone only if patients have not had an adequate response to two or more of 
the other approved DMTs  
^^Licenced for patients with early PPMS in terms of disease duration and level of disability, and with 
imaging features characteristic of inflammatory activity. 
 
 
Box 2. Overview of guidelines for starting, switching and stopping disease-
modifying therapies 
Abbreviations: ABN= Association of British Neurologists; AAN= American Academy of Neurology; 
CIS= clinically isolated syndrome. DMTs= disease-modifying therapies. EAN= European Academy of 
Neurology; ECTRIMS= European Committee for Treatment and Research in Multiple Sclerosis. JCV= 
John Cunningham virus. MS= multiple sclerosis. PPMS= primary progressive multiple sclerosis. 
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Box 2.  Overview of guidelines for starting, switching and stopping disease-modifying therapies 
 
Abbreviations: ABN= Association of British Neurologists; AAN= American Academy of Neurology; CIS= clinically isolated syndrome. DMTs= disease-
modifying therapies. EAN= European Academy of Neurology; ECTRIMS= European Committee for Treatment and Research in Multiple Sclerosis. JCV= John 
Cunningham virus. MS= multiple sclerosis. PPMS= primary progressive multiple sclerosis.  
  ECTRIMS/EAN Guidelines[6]  AAN Guidelines[7] ABN Guidelines[8] 
Starting DMTs - Offer Interferon-β or glatiramer acetate in 
CIS patients with abnormal brain MRI 
- Offer DMTs in patients with active relapsing 
MS 
- Consider treatment with ocrelizumab in 
PPMS 
- Discuss the benefits and risks of DMTs in 
patients with CIS and two or more brain 
lesions 
- Offer DMTs to patients with active relapsing 
MS.  
- Prescribe alemtuzumab, fingolimod or 
natalizumab for highly-active MS 
- Offer ocrelizumab to ambulatory patients with 
PPMS 
- Discuss the benefits of interferon-β or 
glatiramer acetate in CIS patients at high-
risk of MS based on MRI features 
- Offer moderate-efficacy DMTs (30-50% 
decrease in relapse rates) (interferon-β, 
glatiramer acetate, teriflunomide, dimethyl 
fumarate, fingolimod) to patients with active 
relapsing MS 
- Offer high-efficacy DMTs (>50% decrease in 
relapse rates) (natalizumab, alemtuzumab) 
to patients with more active relapsing MS 
Switching DMTs - Offer a more efficacious drug to patients 
treated with Interferon-β or glatiramer 
acetate who have ongoing disease activity 
- Discuss switching DMTs in patients with one 
or more relapses and/or two or more new 
MRI lesions 
- Discuss switching DMTs in patients with side-
effects or persistent laboratory test 
abnormalities  
- Discuss switching DMTs in patients treated 
with natalizumab who are JCV positive 
- Consider switching DMTs in patients with 
ongoing relapses, side-effects, and possibly 
MRI only disease activity 
Stopping DMTs - Consider continuing DMTs in stable 
patients 
- Advocate that patients who are stable 
continue taking DMTs 
- Consider advising stopping DMTs in patients 
with secondary progressive MS who have 
inactive disease and non-ambulatory 
- Consider stopping DMTs prior to conception 
and during pregnancy unless the risk of MS 
disease activity outweighs the benefits 
- Consider stopping DMTs in patients with 
inactive secondary progressive MS 
- Consider stopping DMTs prior to conception 
and during pregnancy 
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Table 1.  Overview of licenced disease-modifying therapies for multiple sclerosis 
DMT Evidence of efficacy from  
phase III pivotal RCTs 
DMT USE AND SAFETY MEASURES IN THE CLINICAL SETTING 
BEFORE (baseline/screening) and AFTER (Follow-up) starting treatment 
Study  
Name 
Sample 
 Size 
Study 
Duration 
Relapse Rate 
Reduction  
Indication Frequency of 
administration  
 Adverse Reactions Treatment Monitoring 
Injectable (subcutaneous or intramuscular injection) 
Glatiramer 
acetate 
 
Copolymer-1 
MS Study 
Group [36] 
 
251 2 years 30%  
vs  
Placebo 
CIS 
RMS 
Variable (three 
times a week, every 
day) 
 
Injection-site reactions, immediate 
post-injection reaction 
Baseline/screening: none  
 
Follow-up: none 
Interferon-β 
preparations 
 
IFNB MS 
STUDY 
GROUP[37] 
248 3 years 34%  
vs  
Placebo 
CIS 
RMS 
Variable (every 
other day, three 
times a week, once 
weekly, every 2 
weeks) 
Flu like illness, injection-site 
reactions, deranged LFTs, 
lymphopenia 
Baseline/screening: FBC, LFTs 
 
Follow-up: FBC, LFTs PRISMS [38] 560 2 years 32% 
Vs 
Placebo 
Oral 
Cladribine 
 
 
CLARITY [39] 
870 96 weeks 58% 
vs 
Placebo 
RMS Two courses of 
treatment over two 
years 
 
Herpes zoster infections, 
lymphopenia, rash, alopecia 
Baseline/screening: FBC, TB, HBV, HIV, 
MRI 
 
Follow-up: FBC 
Dimethyl 
fumarate 
 
 
DEFINE [40] 
818 96 weeks 53% 
vs 
Placebo 
RMS Twice a day 
 
Flushing, gastrointestinal upset, 
lymphopenia, PML (rare) 
Baseline/screening: FBC, LFTs, UEC, 
MRI 
 
Follow-up: FBC with differential every 3 
months, LFTs, UEC, MRI 
CONFIRM 
[41]  
1417 2 years 44% 
Vs  
Placebo 
Fingolimod 
 
 
FREEDOMS 
[42] 
843 24 
months 
55% 
vs 
Placebo 
 
RMS Once a day 
 
First-dose bradycardia, macular 
oedema, herpes zoster, deranged 
LFTs, hypertension, basal cell 
carcinoma, PML (rare) 
Baseline/screening: ECG, OCT, 
dermatologic review, FBC, LFTs, VZV 
(vaccination is needed if VZV-IgG are 
negative), BP.  
 
First-dose cardiac monitoring. 
 
Follow-up: FBC, LFTs, annual skin 
check, BP, OCT at 4 months, MRI 
FREEDOMS II  
 [43] 
713 24 
months 
48% 
Vs 
Placebo 
Teriflunomide 
 
 
TOWER [44] 
758 Variable 
(Minimum 
48 week) 
36% 
vs 
Placebo 
 
CIS 
RMS 
Once a day 
 
Nausea, diarrhoea, hair thinning, 
hypertension, deranged LFTs, 
teratogenicity 
Baseline/screening: FBC, LFTs TB, BP 
 
Follow-up: FBC and LFTs (every 2 weeks 
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TEMSO[45] 721 108 
weeks 
31% 
Vs 
Placebo 
for the first 6 months and every 8 weeks 
thereafter), BP 
Intravenous 
Alemtuzumab 
 
CARE MS I 
[46] 
5
563 
2
2 years  
54%  
vs  
Interferon-β 
RMS Treatment given 
over 2 years: 
- Year 1: once a 
day, for 5 days; 
- Year 2: once a 
day, for 3 days. 
Infusion reactions, infections – 
herpes, varicella, listeria, superficial 
fungal, autoimmunity – ITP, 
nephropathy, thyroid disorders 
leukopenia, lymphopenia 
Baseline/screening: FBC, UEC, LFTs, 
TFTs, TB, HBV, VZV, urinalysis, MRI, 
cervical smear. 
 
Follow-up: FBC, UEC, TFTs, urinalysis, 
MRI 
CARE MS II 
[47] 
6
628 
2
 2 years 
 
50% 
vs 
Interferon-β 
 
Mitoxantrone 
 
Mitoxantrone 
in relapsing-
remitting MS 
[48] 
2 years 51 66% 
vs 
Placebo 
RMS Cumulative dose: 
usually once every 
3 months for 2 
years 
 
Cardiotoxicity, infection, 
myelosuppression, gastrointestinal 
disturbance, alopecia, leukaemia 
and other malignancies 
Baseline/screening: FBC, ECG 
 
Follow-up: FBC, TTE 
Natalizumab 
 
AFFIRM [49] 2 years 942 68%  
vs  
Placebo 
RMS Once every 28 days 
 
Infusion reaction, PML, 
gastrointestinal disturbance, acute 
retinal necrosis (rare) 
Baseline/screening: FBC, LFTs, JCV 
antibody, MRI 
 
Follow-ups: FBC, LFTs, JCV antibody, 
MRI 
Ocrelizumab 
 
OPERA I & 
OPERA II [18] 
96 weeks 1656 55%  
Vs 
 Interferon-β  
RMS 
PPMS 
- Initial 2 doses: 
once two weeks 
apart; 
- Subsequent 
doses: every 6 
months 
Infusion reactions, herpes virus 
associated infections, other 
infections 
Baseline/screening: FBC, HBV, VZV 
 
Follow-up: FBC 
 
Abbreviations: ARR: annualized relapse rate; BP = blood pressure; CIS= clinically isolated syndrome; ECG = electrocardiogram; FBC = full blood count; HBV 
= hepatitis B virus; HIV= human immunodeficiency virus ;  ITP = idiopathic thrombocytopenic purpura; JCV = John-Cunningham virus; LFTs = liver function 
tests; MRI = magnetic resonance imaging; NNT: number needed to treat; OCT = optical coherence tomography; PML = progressive multifocal 
leukoencephalopathy; PPMS= primary progressive multiple sclerosis; RMS= relapsing multiple sclerosis; TB = tuberculosis; TFTs = thyroid function tests; 
TTE = transthoracic echocardiogram; UEC = urea, electrolytes, creatinine; VZV = Varicella Zoster virus. 
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